Regenerative therapy in peripheral artery disease.
Patients with peripheral artery disease (PAD) and critical limb ischemia are the main candidates for limb amputations and have a poor life expectancy. Frequently, these patients are not eligible for either surgical or percutaneous interventions aimed at mechanical revascularization. Therefore, new strategies need to be identified to offer these patients a viable therapeutic option. Gene and cell therapy hold great promise for the treatment of peripheral vascular diseases because, in animal models, local delivery of growth factors and endothelial progenitor cells result in new blood vessel formation and regeneration of ischemic tissues. In this article, are reviewed phase I and phase II gene, and cell therapy clinical trials in patients with PAD.
Germani
Antonia
A
Fondazione Livio Patrizi, Rome, Italy. a.germani@fondazioneliviopatrizi.com
Di Campli
Cristiana
C
Pompilio
Giulio
G
Biglioli
Paolo
P
Capogrossi
Maurizio C
MC
D016026:Bone Marrow Transplantation; D064987:Cell- and Tissue-Based Therapy; D016220:Fibroblast Growth Factor 1 / Q000235:genetics; D015316:Genetic Therapy; D017228:Hepatocyte Growth Factor / Q000235:genetics; D006801:Humans; D051795:Hypoxia-Inducible Factor 1, alpha Subunit / Q000235:genetics; D007963:Leukocytes, Mononuclear / Q000637:transplantation; D016491:Peripheral Vascular Diseases / Q000628:therapy*; D042461:Vascular Endothelial Growth Factor A / Q000235:genetics
C497442:HIF1A protein, human; D051795:Hypoxia-Inducible Factor 1, alpha Subunit; D042461:Vascular Endothelial Growth Factor A; D016220:Fibroblast Growth Factor 1; D017228:Hepatocyte Growth Factor